GRIFFON’s leadership team and board members bring extensive management and clinical development experience.
John Huss, MBA
Chairman, President & CEO, Founder
Mr Huss is a seasoned pharmaceutical executive with more than 28 years of pharmaceutical and biotechnology experience. Mr. Huss founded Griffon Pharmaceuticals Inc. in 2015. Prior to that, he was the President & CEO of Theratechnologies. During his 20-year career in the pharmaceutical industry, he was Global Business Leader for the Cardiovascular Franchise at the Roche Head Office in Basel, Switzerland; Vice-President of Marketing & Sales at Sanofi in Toronto, Canada; CEO of the Swiss affiliate of Sanofi in Geneva, Switzerland; and Chief of Staff at the Sanofi Head Office in Paris, France, reporting to the company’s CEO.
Mr. Huss earned an International Masters degree in Business Administration (MBA) from the University of South Carolina in Columbia, SC, USA.
Krishna Peri, Ph.D.
Chief Scientific Officer, Founder
Krishna Peri is an experienced scientist in developing therapeutic peptides for endocrine, metabolic and inflammatory diseases, with over 20 years of experience working with peptides. Krishna Peri is past VP of Discovery & Preclinical Research at Theratechnologies. Krishna Peri earned his PhD in biochemistry from the University of Saskatchewan.
Marc Cluzel, M.D., Ph.D
Robert Blain, FCPA
Co-CEO of Groupe Lune Rouge and President of Guy Laliberté’s family office, Robert Blain, FCPA, has also contributed to the growth of Cirque du Soleil as its Chief Financial Officer. For over 20 years, he has cultivated relationships with prominent companies, such as MGM, Disney and Apple Corps (Beatles), as well as the trustees of the Michael Jackson and Elvis Presley estates. This long and illustrious career has led him to be involved in various committees and boards of directors; most notably, the One Drop Foundation, the CHU Sainte-Justine Foundation
Senior financial executive with over 25 years in financial management. Strategically focused with international experience that has helped raise in excess $100 million in the capital markets and through a number of licensing and collaboration agreements.